Who
Sunil Agarwal
Director
Company insider
Files Form 4 as: Director, Astria Therapeutics; Director, Arvinas; Director, Calithera Biosciences; EVP, Head of Development & CMO, Sana Biotechnology; Director, MyoKardia; President of R & D, Juno Therapeutics; Chief Medical Officer, Ultragenyx Pharmaceutical.
In numbers
- Trades disclosed
- 94
- Buys
- 0
- Sells
- 15
- Bought
- $0
- Sold
- $4.3M
- Companies
- 7
- Companies where not an officer
- 4
- First trade
- 19 Aug 2014
- Last trade
- 23 Jan 2026
- Last filed
- 23 Jan 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 23 Jan 2026filed 23 Jan 2026 | Astria Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —28,200 | filing |
| 23 Jan 2026filed 23 Jan 2026 | Astria Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —26,550 | filing |
| 23 Jan 2026filed 23 Jan 2026 | Astria Therapeuticsoption or derivative | SEC FORM 4 Code D | —28,200 | filing |
| 23 Jan 2026filed 23 Jan 2026 | Astria Therapeuticsoption or derivative | SEC FORM 4 Code D | —26,550 | filing |
| 25 Jun 2025filed 30 Jun 2025 | ARVN Arvinasoption or derivative · Biotechnology | SEC FORM 4 Code A | —23,105 at $0.00 | filing |
| 25 Jun 2025filed 30 Jun 2025 | ARVN ArvinasBiotechnology | SEC FORM 4 Code A | —16,025 at $0.00 | filing |
| 11 Jun 2025filed 12 Jun 2025 | Astria Therapeuticsoption or derivative | SEC FORM 4 Code A | —26,550 at $0.00 | filing |
| 29 May 2024filed 31 May 2024 | ARVN Arvinasoption or derivative · Biotechnology | SEC FORM 4 Code A | —9,070 at $0.00 | filing |
| 29 May 2024filed 31 May 2024 | ARVN ArvinasBiotechnology | SEC FORM 4 Code A | —5,899 at $0.00 | filing |
| 8 Apr 2024filed 9 Apr 2024 | Astria Therapeuticsoption or derivative | SEC FORM 4 Code A | —28,200 at $0.00 | filing |
| 15 Jun 2023filed 20 Jun 2023 | ARVN Arvinasoption or derivative · Biotechnology | SEC FORM 4 Code A | —24,948 at $0.00 | filing |
| 15 Jun 2023filed 20 Jun 2023 | ARVN ArvinasBiotechnology | SEC FORM 4 Code A | —8,242 at $0.00 | filing |
| 1 Jun 2022filed 3 Jun 2022 | Calithera Biosciencesoption or derivative | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 3 Mar 2022filed 8 Mar 2022 | SANA Sana Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —250,000 at $0.00 | filing |
| 16 Sep 2021filed 17 Sep 2021 | SANA Sana BiotechnologyBiotechnology | SEC FORM 4 Sold | $42K1,627 at $26.00 | filing |
| 15 Sep 2021filed 17 Sep 2021 | SANA Sana BiotechnologyBiotechnology | SEC FORM 4 Sold | $1.5M58,373 at $26.07 | filing |
| 11 Jun 2021filed 14 Jun 2021 | Calithera Biosciencesoption or derivative | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 3 Feb 2021filed 18 Feb 2021 | SANA Sana Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —76,682 at $0.00 | filing |
| 3 Feb 2021filed 5 Feb 2021 | SANA Sana Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —48,000 at $0.00 | filing |
| 17 Nov 2020filed 19 Nov 2020 | MyoKardiaoption or derivative | SEC FORM 4 Code D | —22,000 | filing |
News
Rep. Gilbert Ray Cisneros, Jr. Buys Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)RARE · themarketsdaily.com · 15 Oct 2026Ultragenyx (NASDAQ: RARE) agrees to sell PRV for $203 million in cashRARE · tickerreport.com · 14 Oct 2026
0 headlines in the last 90 days name Sunil Agarwal; 2 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.